WO2010087594A3 - 시디９３ 또는 이의 가용성 단편의 용도 - Google Patents

시디９３ 또는 이의 가용성 단편의 용도 Download PDF

Info

Publication number
WO2010087594A3
WO2010087594A3 PCT/KR2010/000315 KR2010000315W WO2010087594A3 WO 2010087594 A3 WO2010087594 A3 WO 2010087594A3 KR 2010000315 W KR2010000315 W KR 2010000315W WO 2010087594 A3 WO2010087594 A3 WO 2010087594A3
Authority
WO
WIPO (PCT)
Prior art keywords
soluble fragment
specifically binding
antibody specifically
inflammatory diseases
diagnosing
Prior art date
Application number
PCT/KR2010/000315
Other languages
English (en)
French (fr)
Other versions
WO2010087594A9 (ko
WO2010087594A2 (ko
Inventor
박영우
전재원
정준구
최혜인
손명호
김호연
조미라
장영순
문지현
박지현
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090006592A external-priority patent/KR101526307B1/ko
Priority claimed from KR1020090116723A external-priority patent/KR101398545B1/ko
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to JP2011547769A priority Critical patent/JP5752052B2/ja
Priority to EP10735985.3A priority patent/EP2392352B1/en
Priority to US13/146,876 priority patent/US8993343B2/en
Publication of WO2010087594A2 publication Critical patent/WO2010087594A2/ko
Publication of WO2010087594A3 publication Critical patent/WO2010087594A3/ko
Publication of WO2010087594A9 publication Critical patent/WO2010087594A9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)

Abstract

본 발명은 CD93 또는 이의 가용성 단편에 특이적으로 결합하는 항체를 이용한 항염증성 조성물, CD93 또는 이의 가용성 단편에 특이적으로 결합하는 항체 또는 앱타머를 이용한 염증성 질환 진단 방법, 및 염증성 질환 진단 키트에 관한 것이다.
PCT/KR2010/000315 2009-01-28 2010-01-18 시디９３ 또는 이의 가용성 단편의 용도 WO2010087594A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2011547769A JP5752052B2 (ja) 2009-01-28 2010-01-18 Ｃｄ９３またはその可溶性断片の用途
EP10735985.3A EP2392352B1 (en) 2009-01-28 2010-01-18 Cd93 or use of soluble fragment thereof
US13/146,876 US8993343B2 (en) 2009-01-28 2010-01-18 CD93 or use of soluble fragment thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020090006592A KR101526307B1 (ko) 2009-01-28 2009-01-28 항염증성 약학 조성물
KR10-2009-0006592 2009-01-28
KR1020090116723A KR101398545B1 (ko) 2009-11-30 2009-11-30 Ｃｄ93 또는 이의 가용성 단편을 유효성분으로 함유하는 염증성 질환 진단용 마커
KR10-2009-0116723 2009-11-30

Publications (3)

Publication Number Publication Date
WO2010087594A2 WO2010087594A2 (ko) 2010-08-05
WO2010087594A3 true WO2010087594A3 (ko) 2010-10-21
WO2010087594A9 WO2010087594A9 (ko) 2011-11-10

Family

ID=42396160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000315 WO2010087594A2 (ko) 2009-01-28 2010-01-18 시디９３ 또는 이의 가용성 단편의 용도

Country Status (4)

Country Link
US (1) US8993343B2 (ko)
EP (1) EP2392352B1 (ko)
JP (1) JP5752052B2 (ko)
WO (1) WO2010087594A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922958A1 (en) * 2013-09-12 2015-03-19 Teva Pharmaceutical Industries Ltd. Gene expression biomarkers of laquinimod responsiveness
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN110389165A (zh) * 2018-04-23 2019-10-29 江成鸿 Cd93在制备预警婴幼儿血管瘤脐血检测试剂盒及治疗药物中的应用
WO2020180706A1 (en) * 2019-03-02 2020-09-10 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic antigen binding proteins specific for cd93 and methods of use thereof
CN116529260A (zh) * 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
BR112022024629A2 (pt) * 2020-06-02 2023-02-23 Dynamicure Biotechnology Llc Construtos anti-cd93 e seus usos
WO2022032592A1 (en) * 2020-08-13 2022-02-17 Tsinghua University Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
WO2023205706A2 (en) * 2022-04-22 2023-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating idiopathic nephrotic syndrome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5965439A (en) * 1996-11-18 1999-10-12 The Regents Of The University Of California Host defense enhancement
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
JP4338364B2 (ja) 2002-07-02 2009-10-07 ソニー株式会社 携帯情報通信端末、プログラムおよび該プログラムを記録した記録媒体
JP4190223B2 (ja) * 2002-07-19 2008-12-03 照剛 上野 細胞破砕装置及び細胞破砕方法、治療装置並びに細胞成分の選択的分離方法
ATE349538T1 (de) * 2002-09-10 2007-01-15 Natlmmune As Collectin-komplement aktivierende proteinchimären
AU2003299818A1 (en) * 2002-12-20 2004-07-22 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
CA2516128A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
KR100595494B1 (ko) * 2003-02-24 2006-07-03 (주) 디지탈바이오텍 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트
DK1745287T3 (da) * 2004-05-11 2011-01-24 Univ Pittsburgh Diagnostisering og monitorering af inflammatoriske sygdomme ved at måle komplementkomponenter på hvide blodlegemer
DE102005013013A1 (de) * 2005-03-21 2006-09-28 Sirs-Lab Gmbh Verwendung von Genaktivitäts-Klassifikatoren für die in vitro Klassifizierung von Genexpressionsprofilen von Patienten mit infektiösem/nichtinfektiösem Multiorganversagen
US8362224B2 (en) * 2006-12-19 2013-01-29 The Trustees Of The University Of Pennsylvania Screening for CD93 (C1qRp)-associated polymorphism(S) in the diagnosis, prevention and treatment of autoimmune diseases
EP2198008B1 (en) * 2007-10-12 2013-04-10 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Method and kit for rapid isolation of human foxp3+ treg cells
KR200450266Y1 (ko) 2008-02-05 2010-09-16 신호근 건축마감재 줄눈간격결정용 스페이서

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOHLSON S. S. ET AL.: "CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma", J. IMMUNOL., vol. 175, no. 2, 15 July 2005 (2005-07-15), pages 1239 - 1247, XP008152738 *
GHEBREHIWET B. ET AL.: "cClq-R (calreticulin) and gClq-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infectio", MOL. IMMUNOL., vol. 41, no. 2-3, June 2004 (2004-06-01), pages 173 - 183, XP008152739 *
GREENLEE M. C. ET AL.: "CD93 and related family members: their role in innate immunity", CURR DRUG TARGETS, vol. 9, no. 2, February 2008 (2008-02-01), pages 130 - 138, XP008152768 *
GREENLEE M. C. ET AL.: "Detection and characterization of soluble CD93 released during inflammation", INFLAMM. RES., vol. 58, no. 12, December 2009 (2009-12-01), pages 909 - 919, XP019751767 *
NORSWORTHY P. J. ET AL.: "Murine CD93 (ClqRp) contributes to the removal ofapoptotic cells in vivo but is not required for Clq-mediated enhancement of phagocytosis", J. IMMUNOL., vol. 172, no. 6, 15 March 2004 (2004-03-15), pages 3406 - 3414, XP002343686 *

Also Published As

Publication number Publication date
JP2012516322A (ja) 2012-07-19
JP5752052B2 (ja) 2015-07-22
US20120039911A1 (en) 2012-02-16
US8993343B2 (en) 2015-03-31
WO2010087594A9 (ko) 2011-11-10
WO2010087594A2 (ko) 2010-08-05
EP2392352A2 (en) 2011-12-07
EP2392352B1 (en) 2017-10-25
EP2392352A4 (en) 2013-06-26

Similar Documents

Publication Publication Date Title
WO2010087594A3 (ko) 시디９３ 또는 이의 가용성 단편의 용도
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2011075636A3 (en) Wise binding agents and epitopes
WO2011047146A3 (en) Methods of affinity maturing antibodies
WO2012032181A3 (en) Antibody derivatives
WO2012006476A3 (en) Methods and compositions for quantifying exosomes
WO2009135181A3 (en) Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
AU2013257489A1 (en) Cement testing
WO2010102251A3 (en) Il-17 binding proteins
WO2012009567A3 (en) Biomarkers for diagnosis of stroke and its causes
MX2013005015A (es) Anticuerpos anti-il-23.
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2011004028A3 (en) Tlr3 binding agents
EP2350305A4 (en) COMBINATION TREATMENTS WITH PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISEASES
WO2010136483A3 (en) Antigen-binding proteins
WO2010007166A3 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2010009879A3 (en) Methods for producing paricalcitol
WO2011130603A3 (en) Anti-vla-4 antibodies
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
WO2011028883A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2008091948A3 (en) Galectin-3-binding, protein as a biomarker of cardiovascular disease
WO2010141074A3 (en) O-glcnac transferase inhibitors and uses thereof
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10735985

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011547769

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010735985

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010735985

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13146876

Country of ref document: US